THELMA ARARACAP: Open Payments
NPI 1437471059 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,747 in 163 payments from 21 companies in 2025. Trend: 2023 $2,606 · 2024 $3,223 · 2025 $3,747
Food & beverage: $3,747
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 52 | $1,161 |
| Janssen Biotech, Inc. | 26 | $636 |
| PFIZER INC. | 14 | $318 |
| Gilead Sciences, Inc. | 8 | $234 |
| Aimmune Therapeutics, Inc. | 12 | $178 |
| GENZYME CORPORATION | 12 | $165 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $162 |
| Galderma Laboratories, L.P. | 1 | $142 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 5 | $109 |
| Enterra Medical, Inc. | 1 | $109 |
Products named: TREMFYA, CREON, RINVOQ, LINZESS, VELSIPITY, ZENPEP, DUPIXENT, NEMLUVIO.
Industry payments across NV — which companies pay providers there.
